Medivir AB (publ) (STO:MVIR)

Market Cap	1.01B +592.4%
Revenue (ttm)	8.51M +144.1%
Net Income	-94.40M
EPS	-0.66
Shares Out	538.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,216,874
Average Volume	4,160,830
Open	1.904
Previous Close	1.928
Day's Range	1.866 - 1.946
52-Week Range	0.340 - 2.885
Beta	0.11
RSI	43.42
Earnings Date	Apr 29, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phase II studies for treating mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MVIR

Financial Performance

In 2025, Medivir AB's revenue was 8.51 million, an increase of 144.14% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.